Elite in Osteosarcoma

Hans J. Gelderblom

Leiden, ZH, NL 
Elite in Osteosarcoma
Leiden, ZH, NL 
OverviewLocationsClinical Research

Overview

Hans Gelderblom practices in Leiden, Netherlands. Mr. Gelderblom is rated as an Elite expert by MediFind in the treatment of Osteosarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Gastrointestinal Stromal Tumor, Osteosarcoma, Synovectomy, and Osteotomy.

His clinical research consists of co-authoring 414 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 69 articles in the study of Osteosarcoma.

Gender
Male

Locations

Leiden, ZH, Netherlands
Other Locations
Leiden Universitair Medisch Centrum, Leiden
Zuideinde, OV, Netherlands
Amsterdam, NH, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Enrollment Status: Active_not_recruiting
Publish Date: September 05, 2025
Intervention Type: Drug
Study Drug: Entrectinib
Study Phase: Phase 2
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor
Enrollment Status: Active_not_recruiting
Publish Date: July 20, 2025
Intervention Type: Drug
Study Drugs: Ramucirumab, Cyclophosphamide, Vinorelbine
Study Phase: Phase 1/Phase 2
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Synovial Sarcoma
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Synovial Sarcoma
Enrollment Status: Terminated
Publish Date: September 13, 2023
Intervention Type: Drug
Study Drugs: Ramucirumab, Gemcitabine, Docetaxel
Study Phase: Phase 1/Phase 2
View 2 Less Clinical Trials

413 Total Publications

Guidelines for Next-Generation Sequencing in Sarcoma Diagnosis and Treatment: A Consensus Review.
Guidelines for Next-Generation Sequencing in Sarcoma Diagnosis and Treatment: A Consensus Review.
Journal: JAMA oncology
Published: October 16, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Gelderblom's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 9 Advanced Conditions
View All 44 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile